Lanean...
Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti‐interleukin‐5 receptor antibody
Benralizumab is an interleukin‐5 (IL‐5) receptor α‐directed cytolytic monoclonal antibody that reduces rapid and nearly complete depletion of eosinophils by enhancing antibody‐dependent cell‐mediated cytotoxicity. The depletion of eosinophilic inflammation is expected to reduce mucus hypersecretion...
Gorde:
| Argitaratua izan da: | Respirol Case Rep |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Ltd
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7300730/ https://ncbi.nlm.nih.gov/pubmed/32566229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.599 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|